HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Incidence of infective endocarditis in England, 2000-13: a secular trend, interrupted time-series analysis.

AbstractBACKGROUND:
Antibiotic prophylaxis given before invasive dental procedures in patients at risk of developing infective endocarditis has historically been the focus of infective endocarditis prevention. Recent changes in antibiotic prophylaxis guidelines in the USA and Europe have substantially reduced the number of patients for whom antibiotic prophylaxis is recommended. In the UK, guidelines from the National Institute for Health and Clinical Excellence (NICE) recommended complete cessation of antibiotic prophylaxis for prevention of infective endocarditis in March, 2008. We aimed to investigate changes in the prescribing of antibiotic prophylaxis and the incidence of infective endocarditis since the introduction of these guidelines.
METHODS:
We did a retrospective secular trend study, analysed as an interrupted time series, to investigate the effect of antibiotic prophylaxis versus no prophylaxis on the incidence of infective endocarditis in England. We analysed data for the prescription of antibiotic prophylaxis from Jan 1, 2004, to March 31, 2013, and hospital discharge episode statistics for patients with a primary diagnosis of infective endocarditis from Jan 1, 2000, to March 31, 2013. We compared the incidence of infective endocarditis before and after the introduction of the NICE guidelines using segmented regression analysis of the interrupted time series.
FINDINGS:
Prescriptions of antibiotic prophylaxis for the prevention of infective endocarditis fell substantially after introduction of the NICE guidance (mean 10,900 prescriptions per month [Jan 1, 2004, to March 31, 2008] vs 2236 prescriptions per month [April 1, 2008, to March 31, 2013], p<0·0001). Starting in March, 2008, the number of cases of infective endocarditis increased significantly above the projected historical trend, by 0·11 cases per 10 million people per month (95% CI 0·05-0·16, p<0·0001). By March, 2013, 35 more cases per month were reported than would have been expected had the previous trend continued. This increase in the incidence of infective endocarditis was significant for both individuals at high risk of infective endocarditis and those at lower risk.
INTERPRETATION:
Although our data do not establish a causal association, prescriptions of antibiotic prophylaxis have fallen substantially and the incidence of infective endocarditis has increased significantly in England since introduction of the 2008 NICE guidelines.
FUNDING:
Heart Research UK, Simplyhealth, and US National Institutes of Health.
AuthorsMark J Dayer, Simon Jones, Bernard Prendergast, Larry M Baddour, Peter B Lockhart, Martin H Thornhill
JournalLancet (London, England) (Lancet) Vol. 385 Issue 9974 Pg. 1219-28 (Mar 28 2015) ISSN: 1474-547X [Electronic] England
PMID25467569 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier Ltd. All rights reserved.
Chemical References
  • Anti-Bacterial Agents
  • Clindamycin
  • Amoxicillin
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Amoxicillin (administration & dosage)
  • Anti-Bacterial Agents (administration & dosage)
  • Antibiotic Prophylaxis (statistics & numerical data, trends)
  • Clindamycin (administration & dosage)
  • Dental Care (adverse effects)
  • Drug Prescriptions (statistics & numerical data)
  • Endocarditis (epidemiology, etiology, prevention & control)
  • England (epidemiology)
  • Female
  • Humans
  • Incidence
  • Interrupted Time Series Analysis
  • Male
  • Middle Aged
  • Practice Guidelines as Topic
  • Retrospective Studies

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: